1058P A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)

Neoadjuvant chemotherapy (NAC) is the widely Immune checkpoint inaccepted treatment strategy for locally advanced ESCC and has been used in the past decades to downstage and improve the surgical resection rate for this malignancy. Immune checkpoint inhibitors (ICIs) have been shown to be efficient for advanced ESCC, while few studies focus on the neoadjuvant combination of immunotherapy and chemotherapy. To this end, we designed a trial to evaluate the safety and efficacy of toripalimab, a PD-1 inhibitor, combined with nab-paclitaxel (nab-P) and S-1 followed by radical resection surgery for resectable ESCC.